Advertisement

Cancer Causes & Control

, Volume 21, Issue 1, pp 77–82 | Cite as

Leukocyte telomere length in a population-based case–control study of ovarian cancer: a pilot study

  • Lisa Mirabello
  • Montserrat Garcia-Closas
  • Richard Cawthon
  • Jolanta Lissowska
  • Louise A. Brinton
  • Beata Pepłońska
  • Mark E. Sherman
  • Sharon A. Savage
Original paper

Abstract

Objectives

Telomeres are structures at chromosome ends that contribute to maintaining genomic integrity. Telomere shortening with repeated cell divisions may lead to genomic instability and carcinogenesis. Studies suggest that shorter telomeres in constitutional DNA are associated with bladder, breast, lung, and renal cancer. Ovarian cancer tissues also have shortened telomeres and increased telomerase activity, suggesting that telomere abnormalities may be related to ovarian cancer.

Methods

We investigated leukocyte telomere length in 99 women with serous ovarian adenocarcinoma and 100 age-matched cancer-free controls enrolled in a population-based case–control study.

Results

Cases tended to have shorter telomeres than controls (P wilcoxon = 0.002). Compared to subjects with telomere lengths in the longest tertile, those in the middle and shortest tertiles showed respective age-adjusted odds ratios (95% confidence intervals) of 2.69 (1.23–5.88) and 3.39 (1.54–7.46) (P trend = 0.002). Strongest associations were found for subjects with poorly differentiated carcinomas (OR = 4.89, 95% CI 1.93–12.34).

Conclusions

This study shows that short leukocyte telomeres are associated with serous ovarian adenocarcinoma. These findings should be confirmed in large, prospective studies.

Keywords

Ovarian cancer Telomere length Case–control study Epidemiology 

Notes

Acknowledgments

We are grateful to Drs. Mark H. Greene and Phuong Mai of the National Cancer Institute for helpful comments. We thank Neonila Szeszenia-Dabrowska from the Nofer Institute of Occupational Medicine, Lodz, Poland and Witold Zatonski from the Sklodowska-Curie Institute of Oncology and Cancer Center, Warsaw, Poland for their contributions to the study design and conduct; Anita Soni (Westat, Rockville, MD) for her work on study management for the Polish ovarian cancer study; Pei Chao (IMS, Silver Spring, MD) for her work on data and sample management; and physicians, nurses, interviewers and study participants for their efforts during field work. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics and the Center for Cancer Research; National Institutes of Health (grant CA82838); and American Cancer Society (Grant RSG-00-061-04-CCE).

References

  1. 1.
    Moon IK, Jarstfer MB (2007) The human telomere and its relationship to human disease, therapy, and tissue engineering. Front Biosci 12:4595–4620CrossRefPubMedGoogle Scholar
  2. 2.
    Gilley D, Tanaka H, Herbert BS (2005) Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 37:1000–1013CrossRefPubMedGoogle Scholar
  3. 3.
    Maser RS, DePinho RA (2002) Connecting chromosomes, crisis, and cancer. Science 297:565–569CrossRefPubMedGoogle Scholar
  4. 4.
    Stewart SA, Weinberg RA (2006) Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 22:531–557CrossRefPubMedGoogle Scholar
  5. 5.
    Plentz RR, Caselitz M, Bleck JS et al (2004) Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40:80–86CrossRefPubMedGoogle Scholar
  6. 6.
    Rudolph KL, Millard M, Bosenberg MW, DePinho RA (2001) Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28:155–159CrossRefPubMedGoogle Scholar
  7. 7.
    Blasco MA, Lee HW, Hande MP et al (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91:25–34CrossRefPubMedGoogle Scholar
  8. 8.
    Shen J, Terry MB, Gurvich I et al (2007) Short telomere length and breast cancer risk: a study in sister sets. Cancer Res 67:5538–5544CrossRefPubMedGoogle Scholar
  9. 9.
    Jang JS, Choi YY, Lee WK et al (2008) Telomere length and the risk of lung cancer. Cancer Sci 99:1385–1389CrossRefPubMedGoogle Scholar
  10. 10.
    McGrath M, Wong JYY, Michaud D, Hunter DJ, De Vivo I (2007) Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16:815–819CrossRefPubMedGoogle Scholar
  11. 11.
    Wu X, Amos CI, Zhu Y et al (2003) Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95:1211–1218PubMedCrossRefGoogle Scholar
  12. 12.
    Shao L, Wood CG, Zhang D et al (2007) Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178:1492–1496CrossRefPubMedGoogle Scholar
  13. 13.
    Joshua AM, Vukovic B, Braudey I et al (2007) Telomere attrition in isolated high-grade prostaticintraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. Neoplasia 9:81–89CrossRefPubMedGoogle Scholar
  14. 14.
    Kammori M, Takubob K, Nakamurab K et al (2000) Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 159:175–181CrossRefPubMedGoogle Scholar
  15. 15.
    Idei T, Sakamoto H, Yamamoto T (2002) Terminal restriction fragments of telomere are detectable in plasma and their length correlates with clinical status of ovarian cancer patients. J Int Med Res 30:244–250PubMedGoogle Scholar
  16. 16.
    Counter CM, Hirte HW, Bacchetti S, Harley CB (1994) Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91:2900–2904CrossRefPubMedGoogle Scholar
  17. 17.
    Wang SJ, Sakamoto T, Yasuda S et al (2002) The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 84:81–84CrossRefPubMedGoogle Scholar
  18. 18.
    Murakami J, Nagai N, Ohama K, Tahara H, Ide T (1997) Telomerase activity in ovarian tumors. Cancer 80:1085–1092CrossRefPubMedGoogle Scholar
  19. 19.
    García-Closas M, Brinton L, Lissowska J et al (2007) Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case–control study. BMC Cancer 7:60CrossRefPubMedGoogle Scholar
  20. 20.
    Cawthon RM (2009) Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 37:e21CrossRefPubMedGoogle Scholar
  21. 21.
    Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89:932–938CrossRefPubMedGoogle Scholar
  22. 22.
    Shih IM, Kurman RJ (2004) Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMedGoogle Scholar
  23. 23.
    Kurman RJ, Shih I (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160PubMedGoogle Scholar
  24. 24.
    Aviv A, Chen W, Gardner JP et al (2009) Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. Am J Epidemiol 169:323–329CrossRefPubMedGoogle Scholar
  25. 25.
    Unryn BM, Hao D, Gluck S, Riabowol KT (2006) Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res 12:6345–6350CrossRefPubMedGoogle Scholar
  26. 26.
    Fern L, Pallis M, Ian CG et al (2004) Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 126:63–71CrossRefPubMedGoogle Scholar

Copyright information

© US Government 2009

Authors and Affiliations

  • Lisa Mirabello
    • 1
  • Montserrat Garcia-Closas
    • 1
  • Richard Cawthon
    • 2
  • Jolanta Lissowska
    • 3
  • Louise A. Brinton
    • 1
  • Beata Pepłońska
    • 4
  • Mark E. Sherman
    • 1
  • Sharon A. Savage
    • 1
    • 5
  1. 1.Division of Cancer Epidemiology and GeneticsNational Cancer Institute, National Institutes of Health, Department of Health and Human ServicesBethesdaUSA
  2. 2.Department of Human GeneticsUniversity of UtahSalt Lake CityUSA
  3. 3.Department of Cancer Epidemiology and PreventionThe M. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  4. 4.Department of Occupational and Environmental EpidemiologyNofer Institute of Occupational MedicineLodzPoland
  5. 5.Clinical Genetics Branch, Division of Cancer Epidemiology and GeneticsNational Cancer InstituteRockvilleUSA

Personalised recommendations